Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Molecular biology of breast carcinoma.

Literature DB >> 8197767

Molecular biology of breast carcinoma.

Abstract

During the last several years basic research has resulted in the identification of many of the factors involved in signal transduction pathways, leading us to a greater understanding of the mechanisms of growth control in breast cancer cells. Many of these factors are the products of proto-oncogenes or suppressor genes. This review describes the role of some of these factors in breast cancer development, progression, and metastasis and discusses implications for future directions.

Entities: Disease

Mesh：

Substances：

Year: 1994 PMID： 8197767 DOI： 10.1007/bf00348187

Source DB: PubMed Journal: World J Surg ISSN： 0364-2313 Impact factor: 3.352

105 in total

Review 1. Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour.

Authors: D Wynford-Thomas
Journal: J Pathol Date: 1991-11 Impact factor: 7.996

Review 2. Mechanisms of normal and malignant breast epithelial growth regulation.

Authors: M E Lippman; R B Dickson
Journal: J Steroid Biochem Date: 1989 Impact factor: 4.292

3. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation.

Authors: S Y Tsai; J Carlstedt-Duke; N L Weigel; K Dahlman; J A Gustafsson; M J Tsai; B W O'Malley
Journal: Cell Date: 1988-10-21 Impact factor: 41.582

4. An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells.

Authors: L Klein-Hitpass; M Schorpp; U Wagner; G U Ryffel
Journal: Cell Date: 1986-09-26 Impact factor: 41.582

5. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

Authors: C Escot; C Theillet; R Lidereau; F Spyratos; M H Champeme; J Gest; R Callahan
Journal: Proc Natl Acad Sci U S A Date: 1986-07 Impact factor: 11.205

6. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

Authors: H Tsuda; S Hirohashi; Y Shimosato; T Hirota; S Tsugane; H Yamamoto; N Miyajima; K Toyoshima; T Yamamoto; J Yokota
Journal: Cancer Res Date: 1989-06-01 Impact factor: 12.701

7. BCL-1 participates in the 11q13 amplification found in breast cancer.

Authors: C Theillet; J Adnane; P Szepetowski; M P Simon; P Jeanteur; D Birnbaum; P Gaudray
Journal: Oncogene Date: 1990-01 Impact factor: 9.867

8. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation.

Authors: M Koga; R L Sutherland
Journal: J Steroid Biochem Mol Biol Date: 1991-10 Impact factor: 4.292

Molecular biology of breast carcinoma.

Review 1. Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour.

Review 2. Mechanisms of normal and malignant breast epithelial growth regulation.

3. Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation.

4. An estrogen-responsive element derived from the 5' flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells.

5. Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas.

6. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.

7. BCL-1 participates in the 11q13 amplification found in breast cancer.

8. Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation.

9. Identification and characterization of the neurofibromatosis type 1 protein product.

10. Mutation and cancer: statistical study of retinoblastoma.

1. Changes in vascularization of human breast cancer xenografts responding to antiestrogen therapy.

2. Estimating genomic instability mediated by Alu retroelements in breast cancer.

3. Estimation of tumor heterogeneity using CGH array data.

4. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer.